The global Anti-SuicideDrugs Market, by Drug Class (Anti-Depressant and Anti-Anxiety Drugs,Anti-Psychotic Drugs, NMDA Antagonist, Antibiotic Analog), by Region (NorthAmerica, Latin America, Europe, Asia Pacific, Middle East and Africa) wasvalued at US$ 3,818.1 million in 2018 and is projected to expand at a CAGR of4.1% during the forecast period (2019–2027). Introduction of novel approveddrugs, expected to be commercialized post-2020, intended for treatment ofsuicidal ideation would be a major breakthrough for the global anti-suicidedrugs market. Until recently, suicidal ideation has been treated withanti-depressants, anti-anxiety, and anti-psychotic drugs. The trend wouldcontinue until the expected launch of Cyclurad by NeruoRx Pharma during thelatter half of the forecast period (2019–2027). Cyclurad is a combination ofD-cycloserine and Lurasidone and indicated for Acute Suicidal Ideation/Behavior(ASIB) in Bipolar Depression. Other drug candidates are also in the pipeline,intended for treatment of suicidal ideation in major depressive disorder (MDD).
Browse 48 Market Data Tables and44 Figures spread through 150 Pages and in-depth TOC on " Anti-SuicideDrugs Market, by Drug Class (Anti-Depressant and Anti-Anxiety Drugs,Anti-Psychotic Drugs, NMDA Antagonist, Antibiotic Analog), by Region (NorthAmerica, Latin America, Europe, Asia Pacific, Middle East and Africa) - GlobalForecast to 2027"
Suicide is among the majoreconomic burdens to the global economy. According to the World HealthOrganization (WHO), over 800,000 people commit suicide every year. Most of thesuicidal deaths occur in Asia, Africa, and Eastern Europe. Moreover, manysuicidal attempts go unnoticed until and seldom are reported to suicidalprevention organizations, who can help alleviate the issue. Stop Suicide,Yellow Ribbon Suicide Prevention Program, and American Foundation for SuicidePrevention are some of the leading organizations working for preventingsuicides.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/10
Sneha India Foundation is alsoone of the major organization in India who provide 24X7 helpline in order tooffers unconditional emotional support to desperate, depressed and suicidalpeople. High prevalence of depression that leads to suicidal attempts anddeaths would be another stimulus besides the introduction of novel drugs forthe growth of anti-suicide drugs market. According to the FDA, depression actas a disabling and stigmatizing illness which may lead to suicide among youngpeople and adolescents. Thus, launch of specific drugs for suicidal impulses bypharmaceutical companies will prove to be a profitable market in the foreseenfuture. N-Methyl-D-aspartate receptor (NMDAR) agonists and antagonist are theprospective candidate for treating suicidal ideation. Companies banking onanti-depressants and anti-psychotic drugs for treating patients at risk forsuicide should reconsider their strategy, considering these are not veryeffective at addressing the issue. Nonetheless, these drug class are notapproved for use in treating patients at risk for suicide. The globalanti-suicide drugs market has been driven majorly by off-label recommendationsand prescriptions of anti-depressants, anti-anxiety and anti-psychotic drugs.Inadequate reach of healthcare facilities and affordable medications is hinderinggrowth of overall healthcare market in emerging economies such as India, China,Brazil, and Indonesia. Therefore, companies introducing novel anti-suicidaldrugs would be facing a challenge in market penetration in these nations andwould be able to capture only a part of these markets to capitalize on thelucrative growth opportunities in these regions. North America and Europeremain potential markets at initial stages for the anti-suicidal drugs. Highsuicidal rates and accessibility to better medical therapies would be the majorcontributing factors for the anti-suicide drugs market in these regions.
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/anti-suicide-drugs-market-10
Key takeaways of the market:
The global anti-suicide drugsmarket is majorly characterized by the use of anti-depressants, anti-anxietyand anti-psychotic drugs
The global anti-suicide drugsmarket is expected to expand at a CAGR of 4.1% during the forecast period(2019–2027). Rising incidence of suicides across the globe is expected to favorthe market growth for anti-suicide drugs over the forecast period.
Suicidal rates are higher inAsia, Eastern Europe and Africa regions
The antibiotic analog (NMDAagonist) segment in the global anti-suicide drugs market is estimated to begrowing faster post its FDA approval and commercialization
Market growth foranti-depressants and anti-anxiety drugs is projected to be impacted negativelyby the launch of FDA approved anti-suicidal drugs expected towards thelatter-half of the forecast period
Some of the major players presentin the global anti-suicide drugs market are Pfizer, Inc., AstraZeneca plc, EliLilly and Company, Allergan plc, GlaxoSmithKline plc, Merck & Co., Inc., H.Lundbeck A/S, NeuroRx, Inc., and Johnson & Johnson
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/10
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
